AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Middle East & Africa Diabetes Drugs Market Report 2019: Non-Insulin Injectable Drugs, Combination Drugs, & Oral Anti-diabetic Drugs, Insulin Value and Volume 2012-2024 - ResearchAndMarkets.com

May 28, 2019

DUBLIN--(BUSINESS WIRE)--May 28, 2019--

The “Middle East & Africa Diabetes Drugs Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

Market Overview

Scope of the Report

The Middle East & Africa diabetes drugs market is segmented by product type (oral anti-diabetic drugs, insulin, non-insulin injectable drugs, and combination drugs) and geography.

Key Market Trends

Around 16 million People are Suffering from Diabetes in the Middle East & Africa Region

Saudi Arabia Holds the Highest Market Share

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market studied.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Drivers

4.3 Restraints

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Product Type

5.1.1 Oral Anti-diabetic Drugs

5.1.1.1 Biguanide (Value and Volume 2012-2024)

5.1.1.1.1 Metformin

5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)

5.1.1.2.1 Alpha - Glucosidase Inhibitors

5.1.1.3 Sodium - glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

5.1.1.3.1 Invokana (Canagliflozin)

5.1.1.3.2 Jardiance (Empagliflozin)

5.1.1.3.3 Farxiga/Forxiga (Dapagliflozin)

5.1.1.3.4 Suglat (Ipragliflozin)

5.1.1.4 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

5.1.1.4.1 Januvia (Sitagliptin)

5.1.1.4.2 Onglyza (Saxagliptin)

5.1.1.4.3 Tradjenta (Linagliptin)

5.1.1.4.4 Vipidia/Nesina (Alogliptin)

5.1.1.4.5 Galvus (Vildagliptin)

5.1.1.5 Sulfonylureas (Value and Volume 2012-2024)

5.1.1.5.1 Sulfonylureas

5.1.1.6 Meglitinide (Value and Volume 2012-2024)

5.1.1.6.1 Meglitinide

5.1.2 Insulin

5.1.2.1 Basal or Long Acting Insulins

5.1.2.1.1 Lantus (Insulin Glargine)

5.1.2.1.2 Levemir (Insulin Detemir)

5.1.2.1.3 Toujeo (Insulin Glargine)

5.1.2.1.4 Tresiba (Insulin Degludec)

5.1.2.1.5 Basaglar (Insulin Glargine)

5.1.2.2 Bolus or Fast Acting Insulins

5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

5.1.2.2.2 Humalog (Insulin Lispro)

5.1.2.2.3 Apidra (Insulin Glulisine)

5.1.2.3 Traditional Human Insulins

5.1.2.3.1 Novolin/Actrapid/Insulatard

5.1.2.3.2 Humilin

5.1.2.3.3 Insuman

5.1.2.4 Biosimilar Insulins

5.1.2.4.1 Insulin Glargine Biosimilars

5.1.2.4.2 Human Insulin Biosimilars

5.1.3 Non-Insulin Injectable Drugs

5.1.3.1 GLP1 Receptor Agonists

5.1.3.1.1 Victoza (Liraglutide)

5.1.3.1.2 Byetta (Exenatide)

5.1.3.1.3 Bydureon (Exenatide)

5.1.3.1.4 Trulicity (Dulaglutide)

5.1.3.1.5 Lyxumia (Lixisenatide)

5.1.4 Combination Drugs

5.1.4.1 Insulin Combinations

5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

5.1.4.2 Oral Combination

5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

5.2 Geography

6 MARKET INDICATORS

6.1 Type-1 Diabetic Population (2012-2024)

6.2 Type-2 Diabetic Population (2012-2024)

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

7.1.1 Takeda

7.1.2 Pfizer

7.1.3 Eli Lilly

7.1.4 Janssen Pharmaceuticals

7.1.5 Astellas

7.1.6 Boehringer Ingelheim

7.1.7 Merck And Co.

7.1.8 AstraZeneca

7.1.9 Bristol Myers Squibb

7.1.10 Novartis

7.1.11 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/h19rj2

View source version on businesswire.com:https://www.businesswire.com/news/home/20190528005253/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs,Diabetes Drugs

KEYWORD: AFRICA MIDDLE EAST

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/28/2019 04:35 AM/DISC: 05/28/2019 04:35 AM

http://www.businesswire.com/news/home/20190528005253/en

All contents © copyright 2019 The Associated Press. All rights reserved.